QVAR®: Daily Asthma Treatment
Asthma may be a chronic persistent condition. That means that, even on days you aren't feeling asthma symptoms like coughing or trouble breathing, you still need to treat the underlying airway inflammation that causes your asthma symptoms. If you don't control your asthma, it can lead to more severe symptoms and even a greater risk of needing to go to the emergency room.1
QVAR®, a controller medication for asthma, can help reduce persistent asthma symptoms. The QVAR® inhaler is designed for everyday use, delivering a consistent dose of medication to the airways in your lungs.2,3
The medicine in QVAR® is called an inhaled corticosteroid.4 The QVAR® inhaler is designed to deliver this medicine where asthma inflammation exists throughout the lungs.5,6
(beclomethasone dipropionate HFA) Inhalation Aerosol is used in the ongoing treatment of asthma as preventative therapy in patients 5 years of age or older.
is also used for asthma patients who require systemic corticosteroid administration, where adding QVAR®
may reduce or eliminate the need for systemic corticosteroids.
CAUTION: If you are stopping or switching from an oral corticosteroid to QVAR®, follow your doctor's instructions to avoid health risks. (See WARNINGS, Prescribing Information).
- QVAR® does not replace quick-relief inhalers for sudden symptoms.
Inhaled corticosteroids may cause a reduction in growth rate, so children taking QVAR® should have their growth checked regularly. The long-term effect on final adult growth is unknown.
- Do not stop taking QVAR® abruptly without talking to your doctor.
- In clinical studies, common side effects included headache and sore throat. These are not all of the possible side effects of QVAR®. For more information, ask your healthcare provider or pharmacist.
- You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
- NHLBI Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed April 20, 2010.
- Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000;94(suppl B):S3-S9.
- Vanden Burgt J, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane beclomethasone extra fine inhalation aerosol) in asthma. J Allergy Clin Immunol. 2000;106:1209-1224.
- QVAR® (beclomethasone dipropionate HFA) Prescribing Information. Teva Respiratory, LLC. 2012.
- Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
- Leach CL. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:S250-S252.